The most common factors for failure in clinical research include: lack of efficacy, doubts about the clinical safety and negative results toxicological in preclinical evaluation.

Among the objectives of the areas of efficiency and safety it has been prioritized to enhance the capabilities of clinical trials and intensify dialogue with the authorities to reduce time and costs of clinical development, and improvement in patient recruitment. Thus has begun the clinical research setting in motion Best Project, as a platform for excellence in clinical research.

It is required full participation of the hospital pharmacists in the discussion of the protocol both in its development with the developer, as before submission.

Means of communication between the pharmaceutical sponsor researches should increase, delving into the production, management and control samples. As a result of this coordination a more direct relationship with the patient by providing better information on issues related to compliance with the protocol and adverse events should be promoted.